Oxeia Biopharmaceuticals

On a bright Sunday afternoon at Candlestick Park, Alex Smith took a hit. He wasn't knocked out. He remembers the play clearly. But the moment he got up, something was wrong. "I remember being so bright, and as it blurred my vision, something I tried to blink off, it would not go away,"

Alex Smith spoke with Bay Area sports radio host Larry Krueger about Oxeia and its fundraising round.

Oxeia board member Alex Smith and NFL analyst Ryan Tracy discussed why concussion treatment has not changed in a century, its effects beyond football, and Oxeia’s work to bring an FDA-approved drug to market.

In a recent article in Forbes , Tanya Mohn reported that the risk of head injury in a crash is high for e-scooter riders. According to the research by the Germany-based, DEKRA the risk of concussion was nearly 100%. A 2021 study conducted by the University Hospital Zurich and

Oxeia Biopharmaceuticals, a clinical-stage biotech company conducting Phase 2 clinical trials of OXE103 for concussion treatment, announced two board members and additions to its executive leadership team. The company also announced that its headquarters would move from San Diego to Boston.

Dedication to changing the lives of millions of concussion sufferers through scientific advancement

Decades of medical, scientific, and business experience in the drug development and concussion research worlds

Bringing together decades of medical, scientific, and business experience in the drug development and concussion research fields.

Oxeia Biopharmaceuticals, Inc. is headquartered in Boston, MA.

The company aims to bring the first FDA-approved treatment for persistent concussion symptoms to market.